Pursuant to Regulation 30 of SEBI(LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in their meeting held today i.e. February 14, 2026 reconstituted ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories announced on February 14, 2026 that its Board has reconstituted three key committees — the Audit Committee, Stakeholders Relationship Committee, and Nomination and Remuneration Committee — with immediate effect. The change follows the resignation of Ms. Shilpa Bung as Non-Executive Independent Women Director and the appointment of Ms. Khushbu Kachhawa in her place. All three committees now share the same four-member composition, chaired by Mr. Dilip Raj Singhvi, with Ms. Khushbu Kachhawa joining as a member. The committees otherwise retain their existing structure, suggesting a like-for-like swap to maintain continuity in governance.
This is a routine board-level housekeeping change with no impact on operations or financials. Shareholders should note continued stability in committee leadership and majority of members; only the newly appointed independent director will need to be assessed over time.